|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.11.24 - 17:54
|
Amgen Crashes As Anti-Obesity Drug Results Disappoint; Novo & Lilly Surge On Proposed Biden Coverage Rule (ZeroHedge)
|
|
|
Amgen Crashes As Anti-Obesity Drug Results Disappoint; Novo & Lilly Surge On Proposed Biden Coverage Rule
Shares of Eli Lilly and Novo Nordisk surged on Tuesday following news that the Biden administration plans to propose a rule allowing the federal government to cover a significant portion of the tab of "miracle" weight-loss drugs. However, news from Amgen about clinical trial results of its weight-loss drug, while meeting Wall Street expectations, failed to outperform Eli Lilly's blockbuster treatment, Zepbound.
Let's begin with Amgen shares crashing 12% after the Phase 2 study with MariTide showed only a 20% average weight loss at 52 weeks in 592 obese patients.
Wall Street analysts forecasted MariTide would be able to shed about 25% of the patient's body weight on average over the course of one year and exceed the performance of existing drugs offered by Lilly and Novo. About 11% of patients discontinued MariTide during the trial, a much higher discontinuation rate versus the oth...
|
|
|
26.11.24 - 14:52
|
Amgen shares slip as obesity drug data fails to meet high expectations (Reuters EN)
|
|
|
BUZZ-Amgen shares slip as obesity drug data fails to meet high expectations Updates ** Amgen's shares AMGN.O fall ~ 1 1 % to $26 2 in premarket trading ** Co's experimental drug MariTide led to an average weight loss of up to 20% , a result that some analysts had said was the minimum bar for investors ** T he drug's efficacy is in line with that of other approved drugs, but "are on the lower end of the expectations of 20-25%", J efferies analyst Michael Yee said ** AMGN shares tumbled ~7% on Nov...
|
|
|
31.10.24 - 12:20
|
Amgen mit Zahlen, wichtige Adipositas-Daten voraus (Der Aktionaer)
|
|
|
Der US-Biotechkonzern Amgen hat am Mittwoch nach US-Börsenschluss seine Zahlen zum dritten Quartal veröffentlicht. Sowohl Umsatz als auch Gewinn konnten deutlich zulegen. Im Fokus steht aber der Hoffnungsträger MariTide, mit dem sich Amgen einen ordentlichen Anteil am wachsenden Adipositas-Markt sichern will....
|
|
|
|
|
30.10.24 - 21:37
|
Amgen Inc. Q3 Profit Increases, Beats Estimates (AFX)
|
|
|
THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) reported earnings for its third quarter that increased from the same period last year and beat the Street estimates.The company's bottom line came in at......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
